XTL BIOPHARMACEUTICALS LTD
XTLB · Pharmaceutical Preparations · EDGAR filings ↗
Grade
F38gen composite 44pct→64; out of cash (runway <1q); net margin <-100%; net + operating loss
Notable findings
- Going concern● Management has concluded that there is substantial doubt about our ability to continue as a going concern which could prevent us from obtaining new financing on reasonable terms or at all
- No interest coverageInterest coverage -77.57 (cannot cover interest)
- Cash burnNegative free cash flow (-1.7M)
- Net lossNet loss (net margin -227.7%)
- Weak liquidityCurrent ratio 0.61 (<1)
Supply chain
Customers (1)
- Biossil Inc.
Suppliers (1)
- Yeda Research and Development Company Ltd.
Named in the 10-K; linked when we track them.
Key metrics
Gross margin
0.7%
Operating margin
-481.6%
Net margin
-227.7%
Return on equity
-18.9%
Return on assets
-12.0%
ROIC
-30.8%
Debt / equity
0.0×
Interest coverage
-77.6×
Current ratio
0.6×
Free cash flow
-$2M
Tangible book value
-$2M
Cash & investments
$371K
Cash runway
1q
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-06-30 | 2025-12-31 | 0001213900-26-073831 ↗ |
| 20-F | 2025-04-30 | 2024-12-31 | 0001213900-25-037590 ↗ |
| 20-F | 2024-04-30 | 2023-12-31 | 0001213900-24-037717 ↗ |
| 20-F | 2023-03-22 | 2022-12-31 | 0001213900-23-021869 ↗ |
| 20-F | 2022-03-30 | 2021-12-31 | 0001213900-22-016244 ↗ |
| 20-F | 2021-03-15 | 2020-12-31 | 0001213900-21-015290 ↗ |
| 20-F | 2020-03-12 | 2019-12-31 | 0001213900-20-006104 ↗ |
| 20-F | 2019-03-11 | 2018-12-31 | 0001213900-19-003911 ↗ |
| 20-F | 2018-03-15 | 2017-12-31 | 0001213900-18-003028 ↗ |
| 20-F | 2017-03-30 | 2016-12-31 | 0001144204-17-017762 ↗ |
| 20-F | 2016-03-31 | 2015-12-31 | 0001144204-16-091777 ↗ |
| 20-F | 2015-04-28 | 2014-12-31 | 0001144204-15-025405 ↗ |